Recent breakthroughs in stem cell biology and tissue engineering have brought vascularized organoids to the forefront of biomedical research. These advanced three-dimensional models incorporate functional blood vessel networks, overcoming a critical limitation of traditional organoids—the lack of a vascular system. By mimicking the nutrient delivery and waste removal functions of native capillaries, vascularized organoids offer an unprecedented platform for studying human diseases and testing new drugs in a physiologically relevant context. This article explores the design principles, current applications, and emerging challenges in the field of vascularized organoids.

What Are Vascularized Organoids?

Vascularized organoids are miniature, three-dimensional tissue constructs that contain living blood vessel networks. Unlike conventional organoids, which rely on passive diffusion for nutrient and oxygen exchange, vascularized organoids integrate endothelial cells that self-assemble into functional capillaries, arterioles, and venules. This vascular compartment actively perfuses the organoid core, enabling the sustained survival of densely packed cells and the development of more mature tissue architecture.

These models are typically derived from pluripotent stem cells (PSCs) or adult stem cells that are guided to differentiate into multiple cell types, including parenchymal cells (such as hepatocytes or neurons) and supporting stromal cells. The inclusion of endothelial cells—either co-cultured from the same stem cell source or added as a separate population—drives the formation of vascular networks. The resulting organoids can better recapitulate the complex cellular interactions, mechanical forces, and biochemical gradients found in living tissues.

Vascularized organoids are especially valuable for studying diseases where blood vessel dysfunction plays a central role, such as cancer, stroke, diabetic retinopathy, and cardiovascular disorders. They also provide a more accurate platform for drug screening, since drug distribution and toxicity are strongly influenced by vascular transport.

The Need for Vascularization in Organoid Culture

Classic organoids grown in Matrigel or similar hydrogels quickly develop a necrotic core once they exceed a few hundred micrometers in diameter. This diffusion-limited size constraint prevents the formation of large, complex tissues that are necessary for modeling mature human organs. Vascularization overcomes this bottleneck by providing convective transport of oxygen, nutrients, and signaling molecules throughout the organoid volume. Moreover, the presence of endothelial cells establishes important paracrine signaling loops that influence cell differentiation, tissue polarity, and the formation of specialized microenvironments—for example, the blood–brain barrier in cerebral organoids.

Design Strategies for Vascularization

Multiple complementary strategies have been developed to introduce and sustain vasculature within organoids. These approaches range from biochemical manipulation to advanced biofabrication techniques.

Growth Factor Modulation

A fundamental method is the spatiotemporal delivery of angiogenic factors. Vascular endothelial growth factor (VEGF) is the most widely used pro-angiogenic signal, but other molecules such as fibroblast growth factor (FGF), angiopoietin-1, and platelet-derived growth factor (PDGF) are also critical for vessel maturation and stabilization. Researchers modulate these signals by incorporating them into the culture medium, embedding them in slow-release microparticles, or using genetically engineered cells that conditionally express these factors. The timing and gradient of growth factor presentation are carefully controlled to guide the formation of hierarchical vessel structures—from large conduit vessels to fine capillaries.

Co-Culture Systems

A robust strategy involves co-culturing stem cell-derived organoids with endothelial cells, either from a shared progenitor pool or from a separate cell source. For example, when generating kidney organoids, one can differentiate PSCs into both nephron progenitors and endothelial precursors simultaneously. Alternatively, primary human umbilical vein endothelial cells (HUVECs) or induced pluripotent stem cell (iPSC)-derived endothelial cells can be added during the late stages of organoid culture. The endothelial cells invade the organoid and form anastomosing networks that integrate with the host tissue. Advanced co-culture protocols also include pericytes or mesenchymal stromal cells, which stabilize nascent vessels and regulate vascular permeability.

3D Bioprinting

Bioprinting technology enables the precise spatial placement of multiple cell types and biomaterials in a layer-by-layer fashion. This technique can deposit endothelial cells in predefined patterns—for instance, as a core–shell structure—that serve as templates for vessel formation. After printing, the cells reorganize and mature into functional networks. Bioprinting also allows the incorporation of sacrificial materials, such as gelatin or Pluronic F127, which can be washed out to leave behind hollow channels that are then lined with endothelial cells. This approach provides high reproducibility and control over vascular architecture, which is critical for creating organoids with consistent geometry.

Microfluidic Devices and Organ-on-a-Chip Platforms

Microfluidic systems provide dynamic culture conditions that simulate blood flow and shear stress. By connecting organoids to a microfluidic channel network, researchers can perfuse the organoid with culture medium at controlled flow rates. This not only supplies nutrients and removes waste but also exerts mechanical forces that promote endothelial alignment and maturation. Some devices incorporate integrated pumps, sensors, and multi-compartment chambers to mimic organ–organ interactions. For example, a liver-organoid-on-a-chip platform can include separate channels for bile flow and blood flow, replicating the biliary and sinusoidal microenvironments.

Biomaterial Scaffolds and Hydrogels

The extracellular matrix (ECM) plays a crucial role in guiding vascularization. Natural hydrogels like Matrigel, collagen I, and fibrin provide biochemical cues, while synthetic hydrogels based on polyethylene glycol (PEG) or hyaluronic acid can be engineered with specific adhesive ligands and degradation rates. By tuning matrix stiffness, porosity, and biochemical composition, researchers create environments that support endothelial sprouting and anastomosis. Decellularized tissue matrices derived from human organs also offer tissue-specific ECM cues that can promote organoid vascularization.

Applications in Disease Modeling

Vascularized organoids have been applied to model a wide range of pathologies, highlighting the role of vasculature in disease initiation, progression, and therapy response.

Cancer Modeling

Tumor vascularization is a hallmark of cancer progression. Vascularized tumor organoids allow researchers to study how cancer cells recruit blood vessels (angiogenesis), how vessel structure influences metastasis, and how the tumor microenvironment modulates drug delivery. For example, glioblastoma organoids containing functional blood vessels have been used to investigate the blood–brain barrier (BBB) disruption in brain tumors and to screen anti-angiogenic therapies. Similarly, pancreatic ductal adenocarcinoma organoids with integrated vasculature reveal how dense stromal tissue compresses vessels and impedes chemotherapy penetration.

Cardiovascular and Cerebrovascular Disease Models

Vascularized cardiac organoids reproduce the contractile and electrical properties of heart tissue while including coronary-like vessels. These models are used to study myocardial infarction, arrhythmias, and the effects of cardiotoxic drugs. In neurology, cerebral organoids with integrated BBB networks enable the study of stroke, neuroinflammation, and neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases. The inclusion of endothelial cells also allows researchers to investigate the role of vascular dysfunction in neuropathology, including how amyloid-beta deposits affect cerebral blood flow.

Liver and Kidney Disease Models

Liver organoids with a functional sinusoidal network recapitulate drug metabolism, bile secretion, and hepatic fibrosis. They are used to model non-alcoholic steatohepatitis (NASH) and drug-induced liver injury. Similarly, vascularized kidney organoids containing glomerular and tubular structures have been used to study diabetic nephropathy, polycystic kidney disease, and the nephrotoxic effects of chemotherapeutics. The presence of patent blood vessels in these models ensures that metabolic waste products are removed and that test compounds reach target cells in a more physiologically relevant manner.

Drug Testing and Personalized Medicine

The pharmaceutical industry is increasingly turning to vascularized organoids as a platform for drug discovery and preclinical evaluation. These models offer significant advantages over traditional 2D cell cultures and animal models.

High-Throughput Screening

Advances in automated culture systems and imaging technologies have made it possible to produce thousands of vascularized organoids for screening applications. Researchers can evaluate compound libraries for effects on vessel integrity, angiogenesis, tissue viability, and organ-specific functions. By measuring multiple endpoints—such as vessel density, permeability, and parenchymal cell health—in each organoid, they obtain rich datasets that inform lead optimization and toxicity prediction.

Patient-Specific Modeling

Because vascularized organoids can be derived from patient iPSCs, they enable personalized drug testing. A patient's genetic background, including disease-associated mutations, can be recapitulated in the organoid. This approach is particularly powerful for rare diseases and cancers where individual variability affects drug response. For instance, patient-derived tumor organoids with autologous endothelial cells have been used to test combination therapies tailored to the patient's specific tumor microenvironment.

Assessment of Drug Delivery and Biodistribution

Vascularized organoids provide a realistic platform for studying how drugs are transported from the bloodstream into target tissues. Researchers can directly visualize the extravasation of fluorescently labeled compounds or nanoparticles across endothelial barriers. This information is critical for designing drug delivery systems, such as liposomes or polymeric micelles, and for predicting the efficacy of pro-drugs that require metabolic activation. The presence of functional efflux transporters, like P-glycoprotein at the BBB, allows assessment of central nervous system drug penetration.

Challenges and Future Directions

Despite rapid progress, the field of vascularized organoids faces several technical hurdles that must be addressed before these models can be widely adopted in clinical and industrial settings.

Long-Term Stability and Maturation

Many vascularized organoids experience vessel regression after a few weeks in culture. Maintaining perfusable, stable networks requires continuous supply of angiogenic factors and proper pericyte coverage. Researchers are developing bioreactor systems that provide controlled flow and nutrient gradients over extended periods. Additionally, strategies to promote vessel maturation, such as the use of Notch signaling inhibitors or the addition of mural cells, are being refined to create organoids that remain functional for months.

Scalability and Reproducibility

Current protocols often suffer from batch-to-batch variability in vascular network density and architecture. This inconsistency hampers quantitative comparisons across experiments. Standardization of cell sources, culture media, and matrix components is essential. Bioprinting and microfluidic platforms offer routes to more reproducible production, but these technologies must be made affordable and accessible to most laboratories. Automation and real-time monitoring with machine learning algorithms can help standardize organoid quality control.

Replicating Full Tissue Complexity

Human organs contain multiple cell types arranged in intricate 3D structures. Current vascularized organoids typically include only a few cell populations and lack the immune cells, nerves, and stromal components that are critical for many diseases. Future work will integrate additional lineages, such as macrophages, fibroblasts, and lymphatic endothelial cells, to create more complete tissue mimics. Co-culturing organoids with immune cells is particularly important for modeling inflammation and immunotherapy responses.

Regulatory and Translational Considerations

For vascularized organoids to be accepted as preclinical models by regulatory agencies like the FDA, standardized validation protocols must be established. This includes benchmarking organoid responses against clinical data and animal models. Furthermore, the ethical implications of using patient-derived organoids for personalized medicine—especially concerning consent, data privacy, and commercialization—must be carefully addressed. Nonetheless, the potential of these models to reduce animal testing and improve drug development success rates is driving investment and collaboration across academia and industry.

Emerging Technologies and Future Outlook

Looking ahead, several innovations promise to advance vascularized organoid technology. Organ-on-a-chip integration will allow multiple organoids to be linked via vascular channels, creating “body-on-a-chip” systems that model systemic drug effects. The use of gene editing tools like CRISPR-Cas9 will enable the introduction of disease-specific mutations in isogenic organoids, facilitating mechanistic studies. Finally, the integration of real-time sensors and advanced imaging will provide dynamic readouts of organoid function, metabolism, and drug response, accelerating the pace of discovery. As these technologies mature, vascularized organoids are poised to become a cornerstone of personalized medicine and drug development.

For more information on the principles of organoid vascularization, refer to the work published in Nature Reviews Molecular Cell Biology. Additional insights into microfluidic approaches can be found in Lab on a Chip, and the translational potential of patient-derived organoids is discussed in Stem Cells Translational Medicine.